Ua loaʻa iā Glenmark Pharmaceuticals Limited ka ʻae ʻia mai ka mea hoʻoponopono lāʻau India, Drug Controller General of India (DCGI), e hoʻokō i kahi hoʻokolohua lapaʻau Phase 1 o kāna molekele liʻiliʻi hou, GRC 54276, he mea hoʻopaneʻe hematopoietic progenitor kinase 1 (HPK1). ʻO GRC 54276 kekahi o nā molekala hou mai ka kamaʻāina ʻo Glenmark, Innovative Medicines Group, i alakaʻi ʻia e Dr. Nikhil Amin, Luna Nui ʻepekema, loea i ka hoʻomohala ʻana i nā mea molekala hou no nā pono olakino koʻikoʻi. ʻO HPK1 kahi mea hoʻoponopono koʻikoʻi o ka cell T, B cell a me dendritic cell-mediated immune responses, e hoʻomaikaʻi ana i ka pale antitumor ma o ka hoʻoulu ʻana a me ka hoʻomaka ʻana i nā cell T. Ua hōʻike ʻo GRC 54276 i ka hiki ke pepehi i nā cell tumor i nā haʻawina preclinical ma ke ʻano he mea hoʻokahi a me ka hui pū ʻana me nā mea hoʻopaneʻe mākaʻikaʻi, e hoʻolilo iā ia i mea koʻikoʻi nui i ka immuno-oncology.
E loiloi ka haʻawina i ka palekana a me ka hoʻomanawanui ʻana o GRC 54276 ma ke ʻano he monotherapy, a me ka hui pū ʻana me nā mea hoʻopaʻapaʻa checkpoint i nā maʻi me nā maʻi maʻi paʻa paʻa a me ka lymphoma o Hodgkin. E hoʻomaka ʻo Glenmark i ka hoʻokolohua lapaʻau Phase 1 ma India ma Iune 2022, a ke hoʻolālā nei hoʻi e waiho i kahi IND ma US a me Clinical Trial Applications ma ʻEulopa e hoʻomaka i kahi papahana noiʻi lapaʻau holoʻokoʻa.
"ʻO ka hoʻoikaika ʻana o Glenmark e hāʻawi i nā ʻōnaehana lapaʻau hou i kāna mau wahi therapeutic koʻikoʻi. Ua hauʻoli mākou i ka loaʻa ʻana o kā mākou mole molekele hou mai ka 'Innovative Medicines Group' i loko o Glenmark i ʻae ʻia mai ka mea hoʻoponopono lāʻau lapaʻau o India e hoʻomaka i kahi hoʻokolohua lapaʻau Phase 1. Hoʻoikaika kēia i ka ulu ʻana o Glenmark i ka noiʻi lapaʻau hou a he ʻanuʻu kokoke i ka hāʻawi ʻana i nā hopena holoʻokoʻa no ka mālama ʻana i ka maʻi kanesa, "wahi a Glenn Saldanha, Luna Hoʻokele & Luna Hoʻokele, Glenmark Pharmaceuticals Limited.
He aha e lawe ʻia mai kēia ʻatikala:
- Glenmark will initiate Phase 1 clinical trial in India by June 2022, and also plans to file an IND in the US and Clinical Trial Applications in Europe to kick-off a fully global clinical study program.
- GRC 54276 has shown tumor cell killing ability in preclinical studies as a single agent and as well in combination with checkpoint inhibitors, making it a high-priority target in immuno-oncology.
- Glenmark Pharmaceuticals Limited received approval from the Indian drug regulator, Drug Controller General of India (DCGI), to conduct a Phase 1 clinical trial of its novel small-molecule, GRC 54276, a hematopoietic progenitor kinase 1 (HPK1) inhibitor.
